Pacira Biosciences (PCRX) reported Q1 non-GAAP earnings late Thursday of $0.62 per diluted share, unchanged from a year earlier.
Analysts polled by FactSet expected $0.60.
Revenue for the quarter ended March 31 was $168.9 million compared with $167.1 million a year earlier.
Analysts surveyed by FactSet expected $176 million.
The company reiterated its 2025 revenue guidance of $725 million to $765 million. Analysts surveyed by FactSet expect $749.9 million.
Pacira shares were down 7.6% in recent premarket activity Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。